TheraCIM Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Thai FDA Category Presentation/Packing

Concise Prescribing Info

Contents

Nimotuzumab

Indications/Uses

Treatment of relapsed high-grade gliomas in adults (in combination w/ radiation therapy), adolescents & childn; advanced squamous cell carcinoma of the head & neck (SCCHN) w/ concurrent radiotherapy or chemoradiotherapy.

Click to view TheraCIM detailed prescribing information

Dosage/Direction for Use

Relapsed high-grade glioma Adult 200 mg wkly for 6 wk w/ radiation & maintenance of 200 mg every 21 days for 1 yr. Childn & adolescent Induction phase: 150 mg/m² BSA wkly for 6 wk. Consolidation phase: 150 mg/m² BSA every 3 wk until disease progression. Continuous IV infusion SCCHN 200 mg once wkly for 6-8 wk in combination w/ standard radiotherapy or chemoradiotherapy.

Click to view TheraCIM detailed prescribing information

Overdosage

View TheraCIM overdosage for action to be taken in the event of an overdose.

Special Precautions

Patients who have previously received treatment w/ the murine monoclonal Ab ior EGF/r3. History of hypersensitivity to nimotuzumab or NSO mammalian cell-derived products. Patients w/ chronic diseases in decompensate phase eg, cardiac dysfunction, DM or arterial HTN or in patients w/ history of severe allergic reaction. Pregnancy & lactation.

Click to view TheraCIM detailed prescribing information

Use In Pregnancy & Lactation

Click to view TheraCIM detailed prescribing information

Adverse Reactions

Chills, fatigue, headache, nausea, pyrexia, tremors, vomiting; erythema, leucopenia.

Click to view TheraCIM detailed prescribing information

Drug Interactions

Synergistic effects & potentiation of antitumor activity in combination w/ other epidermal growth factor receptor inhibitors.

Click to view TheraCIM detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view TheraCIM detailed prescribing information

Storage

View TheraCIM storage conditions for details to ensure optimal shelf-life.

Description

View TheraCIM description for details of the chemical structure and excipients (inactive components).

Action

View TheraCIM mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01FE - EGFR (Epidermal Growth Factor Receptor) inhibitors ; Used in the treatment of cancer.

Thai FDA Category

Presentation/Packing

Form

TheraCIM soln for inj 50 mg/10 mL

Packing/Price

2 × 1's

TheraCIM

nimotuzumab

Manufacturer:

Innogene Kalbiotech

Distributor:

Alliance Pharma